PTGS2 and colorectal carcinoma: Zelenay and colleagues have reported that COX-2-PGE2 signalling represses the host anti-tumour response to subcutaneous CT26 mouse CRC cell tumours and that COX inhibitors have anti-tumour effects in this model through de-repression of the adaptive anti-tumour immune response [19].